Ascletis Pharma Inc. (Ascletis) (HKEX: 1672), a fully integrated biotechnology company, announced on Sunday that it has dosed its first participant in a global Phase III clinical programme of ASC30 for chronic weight management.
ASC30 is an investigational, proprietary once-daily oral small molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is developed for chronic weight management and diabetes.
The global Phase III clinical programme includes two pivotal, multicentre, randomised, double-blind, placebo-controlled Phase III trials - AURORA-1 (NCT07743463) and AURORA-2 (NCT07743450) - assessing the long-term efficacy, safety, and tolerability of ASC30 once-daily oral tablets in around 4,600 participants across the US, Europe, and Canada.
Ascletis plans to reveal top-line data from the programme in the third quarter of 2028. It is expected to submit a New Drug Application (NDA) to the US Food and Drug Administration (FDA) by the end of 2028 and a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) in early 2029.
Vir Biotechnology's VIR-5500 receives FDA Fast Track designation for prostate cancer
FDA accepts Bayer's application for KERENDIA in chronic kidney disease without diabetes
Okami Medical receives FDA approval for expanded indication of LOBO Vascular Occluder
Kedrion to be honoured at Premier's Supplier Innovation Celebration
Zydus and MSN announce US launch of generic Adempas (Riociguat Tablets)
FDA approves second Reykjavik manufacturing suite for AVT02
Ractigen Therapeutics reports positive first-in-human data for RAG-18 in Duchenne muscular dystrophy
AnnJi Pharmaceutical's AJ201 advances into pivotal Phase 3 trial for SBMA